Onxeo S.A. Stock
€0.11
Your prediction
Onxeo S.A. Stock
Onxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Pros and Cons of Onxeo S.A. in the next few years
Pros
Cons
Performance of Onxeo S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Onxeo S.A. | -7.680% | -9.833% | 12.708% | -65.868% | -28.581% | -85.359% | -87.073% |
| Boiron S.A. | -0.600% | -1.039% | 3.571% | -16.521% | -15.995% | -14.487% | -34.736% |
| Virbac S.A. | 1.090% | 3.938% | 11.128% | 29.877% | 2.925% | 46.047% | 142.136% |
| DBV Technologies S.A. | 0.470% | -6.414% | -5.519% | -58.846% | -32.243% | -87.485% | -91.801% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon examining the financial statements of Onxeo, the company appears to have experienced some fluctuations in its financial performance. It is a company operating in the highly competitive pharmaceutical industry, which could possibly explain the changes observed in its key financial indicators. An in-depth analysis of the financials is necessary to understand the company's strengths and weaknesses, uncovering aspects investors might consider when deciding on its growth potential.
*Pros: *
Increasing Total Assets: The total assets of Onxeo have consistently shown an upward trend from 2019 to 2022, indicating that the company has been effectively deploying its resources and expanding its operations. This growth may reflect positively on the company's future prospects.
